Sort By Categories

Prof. Mohamad Mohty – Multiple myeloma take home messages from ASCO 2021

Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021

Dr. Jordan Gauthier – Results from Phase 3 TRANSFORM Trial

Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021?

Mohamad Mohty – Advances in Multiple Myeloma as reported at EHA 2021

Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021

Jesus G. Berdeja – Results of the CARTITUDE-1 study

Luciano J. Costa – The role of auto in myeloma based on the ASCO 21 data

Saad Usmani – Take-home messages, from ASCO, and EHA 2021

Mehdi Hamadani – Recently released ZUMA-7 trial results

Gram Jackson – Recently released paper on Improving prognostic assignment in older adults with MM

Nitin Jain – Therapy of CLL, what’s new at EHA 2021

Anna Sureda – Therapy of lymphomas, what’s new at EHA 2021

Jurgen Kuball – Gammadelta T cells

Naveen Pemmaraju – Novel Therapeutic Approaches in BPDCN

Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting

Alex Lazaryan – Belumosudil’s FDA approval for cGVHD

Robert Zeiser – REACH3 trial results

Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?

Annalisa Ruggeri – Haplo versus matched unrelated transplant at the era of post-cyclophosphamide

Go to Top